Atlas Trials

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Clinical trial NCT05232409 · RECRUITING

Trial details

NCT number
NCT05232409
Sponsor
Valley Health System
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer MetastaticMetastatic Solid Tumor
Start date
2022-04-17
Primary completion
2028-03-01
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.